Liquidia Corporation
LQDA
Rang in aandelen
#4411
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Aandeelprijs
$38.75
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$3.47B
Verandering (1 dag)
6.60%
Verandering (1 jaar)
73.46%
Land
US
Handel Liquidia Corporation (LQDA)
Categorie
Healthcare
Koersgeschiedenis voor Liquidia Corporation (LQDA)
Hoogste slotkoers: $30.60 op 2026-10-01
Laagste slotkoers: $11.01 op 2018-07-01
Laagste slotkoers: $11.01 op 2018-07-01
Koersgeschiedenis van Liquidia Corporation van 2018 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 42.98% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.44 | 35.30% |
SE
|
|
| $172.38 | 24.64% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
